Collegium Pharmaceutical Inc. ( (COLL) ) has released its Q4 earnings. Here is a breakdown of the information Collegium Pharmaceutical Inc. presented to its investors.
Collegium Pharmaceutical Inc., a biopharmaceutical company focused on pain management and neuropsychiatry, reported record financial results for the fourth quarter and full year of 2024. The company achieved a record net revenue of $181.9 million for the quarter and $631.4 million for the year, driven by strong performance in its pain portfolio and the addition of Jornay PM, a treatment for ADHD.
Key financial highlights include a quarterly GAAP net income of $12.5 million and a full-year net income of $69.2 million. Adjusted EBITDA reached $107.7 million for the quarter and $401.2 million for the year, marking a 9% increase year-over-year. The company ended 2024 with $162.8 million in cash and marketable securities, having repurchased $60 million in shares throughout the year.
Collegium’s strategic initiatives included a 29% year-over-year increase in Jornay PM prescriptions and a 12% increase in Belbuca’s net revenue. The company also appointed Nancy S. Lurker to its Board of Directors and completed the acquisition of Ironshore Therapeutics. Looking ahead, Collegium reaffirmed its 2025 guidance, projecting product revenues between $735 million and $750 million and adjusted EBITDA between $435 million and $450 million.
With a focus on expanding its commercial portfolio and disciplined capital deployment, Collegium is poised for continued growth in 2025. The company’s management remains committed to creating long-term value for shareholders by executing its strategic priorities and leveraging its financial strength.